Physician profile
Tamara Clemetson
NPI 1891888582
$3,161.63
in general payments reported to CMS, 2019-2025
31 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $454 · 2023: $718 · 2024: $731 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,861 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.32 |
| Education | $140.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $836.94 | 2021-2025 | Evenity, Prolia, Otezla |
| Astellas Pharma US INC | $388.89 | 2021-2025 | Veozah |
| Pfizer INC. | $292.71 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $241.34 | 2021-2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $183.61 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $157.98 | 2022-2025 | |
| Lilly USA, LLC | $131.95 | 2021-2025 | Mounjaro, Zepbound, Taltz |
| Novartis Pharmaceuticals Corporation | $129.10 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $97.11 | 2021-2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $77.86 | 2025 | Voquezna |
| Eisai INC. | $69.60 | 2021 | |
| Sanofi-Aventis U.S. LLC | $67.55 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $61.19 | 2023-2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $42.04 | 2024-2025 | Acthar |
| Boston Scientific Corporation | $38.13 | 2022-2025 | Watchman Access System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.91 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $31.20 | 2021 | |
| Smith+Nephew, INC. | $30.89 | 2022-2023 | Grafix Pl |
| Neurocrine Biosciences, INC. | $30.82 | 2025 | |
| Xeris Pharmaceuticals, INC. | $29.34 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $22.12 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $20.62 | 2021 | |
| Ucb, INC. | $20.01 | 2023 | Cimzia |
| Verona Pharma, INC. | $18.47 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $17.40 | 2025 | Saphnelo |
| Irhythm Technologies, INC. | $17.31 | 2024 | Zio Xt Patch |
| Otsuka America Pharmaceutical, INC. | $16.52 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $14.27 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.84 | 2022 | |
| Exact Sciences Corporation | $13.10 | 2024 | Cologuard Collection Kit |
| Radius Health, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Clemetson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.